GILEAD SCIENCES EXERCISES OPTION TO ACQUIRE CORUS PHARMA FOR $365 MILLION

Gilead Sciences, Inc. announced that the company has exercised its option to purchase privately held Corus Pharma for $365 million. The transaction is expected to close in the third quarter, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and is expected to be dilutive to Gilead's 2006 and 2007 earnings.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=4080954)